Abstract
Objective: To investigate the significance of treatment with antithyroid drugs longer than 12 months on lasting remission in Graves’ hyperthyroid patients, and to study clinical and laboratory parameters of prognostic value. Patients: Fifty-two untreated Graves’ hyperthyroid patients were assigned at random to two therapeutic groups. They were treated with Carbimazole during 12 and 24 months in Group I (n= 28) and Group II (n= 24), respectively. Measurements: Serum levels of FT4, T3, sTSH and TSH receptor antibody (TRAb) were measured before starting treatment and at regular intervals during treatment and follow-up after drug withdrawal. We compared the relapse rate in both groups of patients, at short (2-yr) and long-term (5-yr) periods after drug withdrawal. Also, we compared clinical and biochemical parameters between patients who stayed in remission and who had relapse. Results: At the end of the short-term period, relapse had occurred in 13 (46.4%) Group I patients and in 13 (54.1%) Group II patients, p=0.36. At the end of the long-term period, relapse had occurred in 24 (85.7%) Group I and 20 (83.3%) Group II patients, p=0.78. No difference could be observed between patients who had stayed in remission and who had suffered relapse, within the 5-yr follow-up period regarding to goiter size, frequency of ophthalmopathy, TSH and TRAb levels. Conclusions: The high relapse rate observed could be due to high iodine intake in our country. In this study and in a review of the available data, we have been unable to find any rational basis for courses of antithyroid drugs longer than twelve months for the treatment of Graves’ hyperthyroidism. Nor is a reliable prognosis for an individual patient possible by TRAb determination at any given time during therapy, owing to the low sensitivity and specificity of this variable.
Similar content being viewed by others
References
Laurberg P., Hansen P.E., Iversen E., Jensen S.E., Weete J. Goitre size and outcome of medical treatment of Graves’ disease. Acta Endocrinol. (Copenh.) 111: 39, 1986.
Takamatsu J., Kuma K., Mozai T. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves’ disease. J. Clin. Endocrinol. Metab. 62: 980, 1986.
Wilson R., McKillop J.H., Henderson N., Pearson D.W., Thomson J.A. The ability of the serum thyrotrophin receptor antibody (TRab) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves’ disease. Clin. Endocrinol. (Oxf.) 25: 151, 1986.
Winsa A., Dahlberg P.A., Jansson R., Agren H., Karlsson F.A. Factors influencing the outcome of thyrostatic drug therapy in Graves’ disease. Acta Endocrinol. (Copenh.) 122: 622, 1990.
Hedley A.J., Young R.E., Jones S.J., Alexander W.D., Bewsher P.D., Scottish automated follow-up register group. Antithyroid drugs in the treatment of hyperthyroidism of Graves’ disease: long-term follow-up of 434 patients. Clin. Endocrinol. (Oxf.) 31: 209, 1989.
Schleusener H., Schwander J., Fisher C., Hollo R., Holl G., Badenhoop K., Hensen J., Finke R., Bogner U., Mayr W.R., Schernthaner G., Schatz H., Pickardt C.R., Kotulla P. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves’ disease. Acta Endocrinol. (Copenh.) 120: 689, 1989.
Tamai H., Nakagawa T., Fikino O., Shinzato S. Thionamide therapy in Graves’ disease: relation of relapse to duration of therapy. Ann. Intern. Med. 92: 488, 1980.
Lippe B.M., Landaw E.M., Kaplan S.A. Hyperthyroidism in children treated with long medical therapy: Twenty-five percent remission every two years. J. Clin. Endocrinol. Metab. 64: 1241, 1987.
Allannic H., Fauchet R., Orgiazzi J., Madec A.M., Genetet B., Lorcy Y., Le Guerrier A.M., Delambre C., Derennes V. Antithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of treatment duration. J. Clin. Endocrinol. Metab. 70: 675, 1990.
Schleusener H., Schernthaner G., Mayr W.R., Kotula P., Bogner U., Finke E., Meinhold H., Koppenhagen K., Wenzel K.W. HLA-DR3-DR4 and HLA-DR5 associated thyrotoxicosis: two different types of toxic diffuse goitre. J. Clin. Endocrinol. Metab. 56: 781, 1983.
Romaldini J.H., Bromberg N., Werner R.S., Tanaka L.M., Rodrigues H.F., Werner M., Farah C.S., Reis L.C.F. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 57: 563, 1983.
Pinchera A., Liberti P., Martino E., Fenzi G.F., Grasso L., Rovis L., Baschieri L., Doria G. Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies. J. Clin. Endocrinol. Metab. 29: 231, 1969.
McGregor A.M., Petersen M.M., McLachlan S.M., Rooke P., Rees Smith B., Hall R. Carbimazole and the autoimmune response in Graves’ disease. N. Engl. J. Med. 303: 302, 1980.
Weetman A.P., McGregor A.M., Hall R. Evidence for an effect of antithyroid drugs on the natural history of Graves’ disease. Clin. Endocrinol. (Oxf.) 21: 163, 1984.
Davies T.F., Yeo P.P.B., Evered D.C., Clark F., Rees Smith B., Hall R. Value of thyroid-stimulating antibody determination in predicting short-term thyrotoxicosis relapse in Graves’ disease. Lancet 1: 1181, 1977.
Teng C.S., Yeung R.T.T. Changes in thyroid stimulating antibody activity in Graves’ disease treated with antithyroid drugs and its relationship to relapse: a prospective study. J. Clin. Endocrinol. Metab. 50: 144, 1980.
Weetman A.P., Ratanachaiyavong S., Middleton G.W., Love W., John R., Owen G.M., Darke C., Lazarus J.H., Hall R., McGregor A.M. Prediction of outcome in Graves’ disease after Carbimazole treatment. Quart. J. Med. 59: 409, 1986.
Mazzaferri E.L. In: Skillman T.G. (Ed.), Endocrinology case studies, ed. 2. Hans Huber Publishers, Bern 1975, p.13.
Crooks J., Murray I.P.C., Wayne E.J. Statistical methods applied to the clinical diagnosis of thyrotoxicosis. Quart. J. Med. 28: 211, 1959.
García-Mayor R.V.G., Gómez Sobreira M., Batista J., Moreiras M., Lázaro Enguis J., Alvarez Gándara D. Disfunción tiroidea clínica en pacientes tratados crónicamente con amiodarona. Rev. Esp. Cardiol. 43: 227, 1990.
García-Mayor R.V.G., Cobas P. Resultados del tratamiento de la enfermedad de Basedow-Graves con antitiroideos. Estudio prospectivo. Endocrinologia 29: 56, 1982.
Rios Santomé M., García-Mayor R.V.G., Fernández M., Lago Y., Blanco V., Vázquez E. El bocio endémico en el sur de Galicia. Estudio epidemiológico. Ann. Med. Inter. (Madrid) 4: 379, 1987.
Wartofsky L. Low remission after therapy for Graves’ disease. Possible relation of dietary iodine with antithyroid therapy results. JAMA 226: 1083, 1973.
Yamamoto M., Igarashi T., Kimura S., Tsukamoto S., Togawa K., Ogata E. Thyroid suppression test and outcome of hyperthyroidism treated with antithyroid drugs and triiodothyronine. J. Clin. Endocrinol. Metab. 48: 72, 1979.
Hershman J.M., Givens J.R., Cassidy C.E., Astwood E.B. Long-term outcome of hyperthyroidism treated with antithyroid drugs. J. Clin. Endocrinol. Metab. 26: 803, 1966.
Glinoer D., Hesch D., Lagasse R., Laurberg P. The management of hyperthyroidism due to Graves’ disease in Europe in 1986. Results of an international survey. Acta Endocrinol. (Copenh.) 115 (Suppl. 185): 1, 1987.
Slingerland D.W., Burrows B.A. Long term antithyroid treatment in hyperthyroidism. JAMA 242: 2408, 1979.
Madec A.M., Laurent M.S., Lorcy Y., Leguerrier A., Rostagnat-Stefanutti A., Orgiazzi J., Allannic M. Thyroid stimulating antibodies: an aid to the strategy treatment of Graves’ disease. Clin. Endocrinol. (Oxf.) 21: 247, 1984.
Greer M.A., Kamper H., Bouma D.J. Short term antithyroid drug therapy for the thyrotoxicosis of Graves’ disease. N. Engl. J. Med. 297: 173, 1977.
Bing R.F., Rosenthal F.D. Early remission in thyrotoxicosis produced by short courses of treatment. Acta Endocrinol. (Copenh.) 100: 221, 1982.
Bouma D.J., Kammer H., Greer M.A. Follow-up comparison of short term 1-year antithyroid drug therapy for the thyrotoxicosis of Graves’ disease. J. Clin. Endocrinol. Metab. 25: 1138, 1982.
Meng W., Meng S., Stöwhas H., Männchen E., Ventz M., Hampel R. Ergebnisse der thyreostatischen Langzeittherapie der Hyperthyreose. Einflub der Struma, der Orbitopathie und der Behandlungsdauer. Deuts. Ges. Wesen. 37: 1956, 1982.
Fenzi G., Hashizume K., Roudebush C.P., DeGroot L.J. Changes in thyroid-stimulating immunoglobulins during antithyroid therapy. J. Clin. Endocrinol. Metab. 48: 572, 1979.
McGregor A.M., Rees Smith B., Petersen M.M., Miller H., Dewar P.J. Prediction of relapse in hyperthyroid Graves’ disease. Lancet 1: 1101, 1980.
Edan G., Massart C., Poirier J.Y., Lé Reun M., Hespel J.P., Ledech G., Simon M. Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves’ disease. Br. Med. J. 298: 359, 1989.
Author information
Authors and Affiliations
Additional information
This work was supported by Grant FISss 89/127-F-3 from Fondo de Investigación of Spanish Ministry of Health.
Rights and permissions
About this article
Cite this article
García-Mayor, R.V.G., Páramo, C., Cano, R.L. et al. Antithyroid drug and Graves’ hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Invest 15, 815–820 (1992). https://doi.org/10.1007/BF03348811
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348811